• CEO Lena Degling Wikingsson MSc, PhD

    Lena Degling Wikingsson is a pharmacist by training and holds a PhD in Pharmaceutical Science. She has nearly 20 years of experience in the pharmaceutical industry and has previously been CEO of Independent Pharmaceutica AB and Avaris AB, a non-executive Director of Avaris AB and Eurocine Vaccines AB, has held positions at SBL Vaccines, Accuro Immunology, and was biotechnology assessor at the Medicinal Products Agency of Sweden. She has broad experience in regulatory affairs and development of biologics and vaccines as well as extensive management and development experience in life science. Lena is currently non-executive Director of Simplexia and CellProtect Pharmaceuticals. 

  • CMO Gunvor Ekman-Ordeberg MD, PhD

    Since becoming a Specialist in Ob/Gyn in 1977 and earning her PhD 1982, Gunvor Ekman-Ordeberg has held leading positions at Karolinska Institutet, including Head of Obstetrics (1986-2000) and Professor of Obstetrics and Gynecology (2001-present). In 1986, Dr. Ekman-Ordeberg became the head of a research group with an international network and 25 PhDs from different countries. Dilafor originates from a clinical observation by Dr. Ekman-Ordeberg in the early 1980s which indicated that prophylactic LMWH was associated with an effective labor in term pregnant women. Dr. Ekman-Ordeberg and the research group have studied the delivery process in the clinics and in human biopsies for more than 35 years. Findings from these experiments supported the clinical observations which formed the basis of the founding of Dilafor 2003.

  • Head of Clinical Operations Anette Bergstén

    Anette is a registered nurse and has studied business administration at the University of Stockholm. She has more than 20 years of experience from the pharmaceutical industry at companies such as J&J, Pfizer and Roche, with various positions in clinical research and marketing.

  • Head of Safety Per Blom MD, PhD

    Senior Advisor Clinical Development Per Blom has a background in Physiology Research and more than 25 years of experience from clinical drug development at Pharmacia and Linde Healthcare, and as a consultant to small- and medium-sized companies.

  • Head of R&D Erik Holmer BSc, PhD

    Erik Holmer earned a PhD in Biochemistry in 1987. From 1973 to 1989, he held various positions in the R&D dept. of KabiVitrum (later Pharmacia Corp), primarily in managing research in the field of coagulation, thrombosis and hemostasis, heparin and development of new antithrombotic agents. Dr. Holmer is the co-inventor and project leader for the development of the Low-Molecular-Weight-Heparin Fragmin (1978-1989). From 1990 to 2004, he held the position of Director of R&D at Carmeda AB, a subsidiary of W.L. Gore & Associates, Inc., where he led the development of heparin-based blood compatible surface coatings for medical devices. Dr. Holmer is a Co-founder of Dilafor.

  • Head of Manufacturing Per-Olov Eriksson

    Per-Olov Eriksson is a Process Development Scientist by training, focusing on heparin, LMWH and derivatives thereof as well as recombinant proteins, MaBs development and their manufacturing. He has 30 years of experience from the pharmaceutical industry and was Director of Process Development at Pharmacia and at Esperion Therapeutics Inc, both in USA. He has broad experience in heparin and LMWH manufacturing, where he led the startup of the facility for Fragmin production and continued to work with heparin process development and production. Per-Olov is a Co-founder of Dilafor.

  • Head of Non-Clinical Safety and Toxicology Kjell Gunnarsson

    Kjell Gunnarsson is a Doctor of Veterinary Medicine by training and specialized in veterinary and laboratory animal pathology. He is a European Registered Toxicologist (ERT) specialized in Non-Clinical Toxicology and Safety assessment of pharmaceutical products from early clinical development to registration. Kjell has more than 30 years of experience in the pharmaceutical industry and has been Head of Toxicology in LEO, Helsingborg (1972 - 1991) and Corporate Director for Toxicology and Safety Assessment in Kabi Pharmacia Sweden (1991 - 1996). From 1996 - 2005, he was Director of Toxicology and Director of Regulatory Toxicology at Pharmacia & Upjohn/WWT Italy. Since 2005, he has been a consultant in Toxicology and Safety Assessment for pharmacutical research companies in Sweden. Kjell is a Co-founder of Dilafor.

  • Head of Intellectual Property Ann-Sofie Sternås

    Ann-Sofie Sternås is an authorized European Patent Attorney with more than 25 years of experience in IP/patent matters from the pharmaceutical industry, including almost 20 years working as an in-house attorney in “big pharma” companies (Astra/AstraZeneca, Pharmacia). The majority of these years have been spent Ann-Sofie working with IP-related matters from a global perspective, including more than 10 years of heavy involvement in the IP litigation of several blockbuster drugs. From 2012 to 2015, she was employed at the investment company Karolinska Development AB. Ann-Sofie has in-depth understanding and knowledge of strategic IP matters, with a heavy focus on the US legislation, particularly regarding IP matters in the interface between patent legislation and regulatory laws.

  • Head Quality Assurance GMP Göran Kvist MSc Pharm

    Göran Kvist received a M.Sc. Pharm. in Biochemistry from the University of Uppsala, Sweden, 1982.Mr Kvist has 16 years of professional experience from Quality Assurance & Control in international biotech and large pharmaceutical companies, as former Pharmacia Corporation and Ferring Group. Mr Kvist is the CEO for the GMP consulting company, TQ Kvalitetskonsult AB, since 1999. He is also co-founder and board member of QP Support AB since its inception in 2007, focusing on quality systems and auditing according to cGMP in both EU, North America and Asia. Mr Kvist ia a co-founder of Dilafor.  He is also board member of AcuCort AB and Trophea AB.